Epigenomics
Berlin
About Epigenomics
Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer. Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself. The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $105.8M
- Funding stage: M&A
- Last round: Grant (Jul 2015)
- Ticker: fra:ECX
- Website: epigenomics.com
- Phone: +49 30 24345-0
Industries & Categories
Biotechnology, Health Diagnostics, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/epigenomics-3176905 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.